Albumin Substitution in Decompensated Liver Cirrhosis: Don't Forget Zinc.
Ontology highlight
ABSTRACT: Decompensated liver cirrhosis has a dismal prognosis, with patients surviving on average for 2-4 years after the first diagnosis of ascites. Albumin is an important tool in the therapy of cirrhotic ascites. By virtue of its oncotic properties, it reduces the risk of cardiovascular dysfunction after paracentesis. Treatment with albumin also counteracts the development of hepatorenal syndrome and spontaneous bacterial peritonitis. More recently, the positive impact of long-term albumin supplementation in liver disease, based on its pleiotropic non-oncotic activities, has been recognized. These include transport of endo- and exogenous substances, anti-inflammatory, antioxidant and immunomodulatory activities, and stabilizing effects on the endothelium. Besides the growing recognition that eff
SUBMITTER: Grungreiff K
PROVIDER: S-EPMC8618355 | biostudies-literature | 2021 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA